Development of AgPlus rapid electrochemical immunoassays for COVID-19

针对 COVID-19 的 AgPlus 快速电化学免疫分析的开发

• 批准号: 73615
• 金额: $ 22.28万
• 依托单位: AGPLUS DIAGNOSTICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=73615
• 关键词: Development; AgPlus; rapid; electrochemical; immunoassays

SARS-CoV-2 or COVID-19 is virus that is currently spreading throughout the world. Relatively little is understood about the virus but we are learning fast and it is clear that we need to have good diagnosis to support quarantine and treatment. What is known is that the virus has a serial interval of 4 days and 1-3% of the population may be pre-symptomatic but still transmitting the virus. It takes 2-14 days to show symptoms after infection with the 97% of people developing symptoms within 11.5 days. There is a clear global challenge to halt the spread of this disease and to strengthen the ability of all healthcare systems to cope better with future epidemics.Key to this is accurate fast diagnostic testing for the virus or immune status of patients. AgPlus' diagnostic assays for detecting specific immune responses to the COVID-19 virus will allow for a) confirmatory testing (rule in rule out) of those with symptoms, understanding that in some instances the symptoms may be due to bacterial infection b) monitoring treatment efficacy in those that have tested positive to ensure they are responding and when safe to release from isolation c) potential to be a companion diagnostic to support drug/ vaccine development and d) to determine if you have had a COVID-19 infection.

SARS-CoV-2或COVID-19是目前在世界各地传播的病毒。人们对这种病毒的了解相对较少，但我们正在快速学习，很明显，我们需要有良好的诊断来支持隔离和治疗。已知的是，该病毒的连续间隔为4天，1-3%的人口可能出现症状前，但仍在传播病毒。感染后2-14天出现症状，97%的人在11.5天内出现症状。制止这一疾病的传播和加强所有卫生保健系统更好地应对未来流行病的能力是一项明显的全球挑战。关键是对患者的病毒或免疫状态进行准确快速的诊断测试。AgPlus用于检测对COVID-19病毒的特异性免疫反应的诊断分析将允许a)对有症状的人进行确证性检测（排除规则）；理解在某些情况下，症状可能是由细菌感染引起的；b)监测检测呈阳性的患者的治疗效果，以确保他们有反应，以及何时可以安全解除隔离；c)可能成为支持药物/疫苗开发的伴随诊断；d)确定您是否感染过COVID-19。